Momelotinib, previously identified to treat myeloproliferative neoplasm, showed downregulation of PNPLA3 mRNA, representing a new and effective therapeutic approach for NASH (48). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatohepatitis.